Elanco Animal Health Incorporated
ELAN Healthcare Drug Manufacturers Specialty & Generic
Elanco Animal Health Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 6.22% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 450.0%, free cash flow grew 35.6% and total debt fell 6.91%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow ELAN
Elanco Animal Health Incorporated (ELAN) EV/Sales
As of 16 October 2026, Elanco Animal Health Incorporated (ELAN) trades at a EV/Sales of 3.0×. Over the past ten years it has ranged from 0.0× (September 2018) to 7.2× (October 2020); the current reading is higher than 40% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.1× | 40.76% |
| FY2024 | 2.2× | (22.51%) |
| FY2023 | 2.9× | 9.46% |
| FY2022 | 2.6× | (36.21%) |
| FY2021 | 4.1× | (30.09%) |
| FY2020 | 5.9× | 39.69% |
| FY2019 | 4.2× | 10.04% |
| FY2018 | 3.8× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.1× | (1.22%) |
| Mar 2026 | 3.2× | 1.39% |
| Dec 2025 | 3.1× | 5.87% |
| Sep 2025 | 2.9× | 22.75% |
| 31 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VTRS Viatris Inc. compare | 2.3× |
| HIMS Hims & Hers Health, Inc. compare | 2.7× |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 2.8× |
| RDY Dr. Reddy's Laboratories Ltd compare | 2.9× |
| ELAN Elanco Animal Health Incorporated | 3.0× |
| NBIX Neurocrine Biosciences, Inc. compare | 4.1× |
| LNTH Lantheus Holdings, Inc. compare | 4.2× |
| ALKS Alkermes plc compare | 4.6× |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 6.6× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)